• Management will address questions during a Q&A portion of the call related to WEED’s business and financial results
  • Verified shareholders can also submit and upvote questions in advance using a platform developed by Say Technologies
  • Following the release of its first quarter fiscal year 2023 financial results, the company will host a live audio webcast
  • Canopy Growth Corp. (WEED) was down 3.92 per cent trading at C$1.16 as of 10:53 am EDT

Canopy Growth Corporation (WEED) will release its Q1 FY2023 financial results before financial markets open on August 5, 2022.

Following the release of its financial results, Canopy Growth will host an audio webcast with David Klein, CEO and Judy Hong, CFO on August 5, 2022, at 10:00 am EDT.

Management will address questions during a Q&A portion of the call related to Canopy Growth’s business and financial results.

Additionally, verified shareholders can submit and upvote questions in advance using a platform developed by Say Technologies.

A live audio webcast will be available at https://app.webinar.net/bXk1q7d6DRl.

Canopy Growth is a world-leading diversified cannabis and cannabinoid-based consumer product company, driven by a passion to improve lives, end prohibition, and strengthen communities by unleashing the full potential of cannabis.

Leveraging consumer insights and innovation, WEED offers product varieties in high-quality dried flower, oil, softgel capsule, infused beverage, edible, and topical formats, as well as vaporizer devices by Canopy Growth and industry-leader Storz & Bickel.

Canopy Growth Corp. (WEED) was down 3.92 per cent trading at C$1.16 as of 10:53 am EDT.


More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.